Multiple Myeloma Patient Registry

Stopped early

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to document the participants characteristics, disease burden, and clinical management of participants in the United States who are treated for relapsed multiple myeloma in routine medical practice with a treatment strategies that include a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments.

Key facts

Study ID

NCT03180853

Run by

Janssen Scientific Affairs, LLC

People needed

85

Starts

2017-05-08

Expected to finish

2018-04-06

Last updated by the study team

2025-02-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must sign, and/or their legally acceptable representative where applicable must sign, a participation agreement/informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements
• Have a diagnosis of relapsed MM [according to 2014 International Myeloma Working Group (IMWG) criteria] with 1 to 3 prior lines of therapy. (An induction regimen followed by autologous stem cell transplantation and single-agent maintenance therapy will be considered a single line of therapy.)
• Participants must have initiated a new line of induction therapy that includes a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) within 90 days prior to enrollment. A short course of corticosteroids is allowed prior to initiating the new line of induction therapy
• Must be willing and able to complete the protocol-required patient-reported outcome (PROs)

You may not qualify if…

• Participant has plasma cell leukemia [greater than (>) 2.0 * 10\^9 per liter] circulating plasma cells by standard differential), Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and/or skin changes), or amyloid light-chain amyloidosis
• Participant has a life expectancy of less than 6 months
• At the time of screening, participant is enrolled in an interventional clinical trial for MM using an anti-neoplastic agent that is not currently approved by the United States (US) Food and Drug Administration (FDA)

Where it is running

• Mercy Research — Fort Smith, Arkansas, United States
• Genesis Cancer Center — Hot Springs, Arkansas, United States
• St. Bernard's Medical Center — Jonesboro, Arkansas, United States
• CARTI — Little Rock, Arkansas, United States
• Facey Medical Group — Mission Hills, California, United States
• North County Oncology — Oceanside, California, United States
• Ventura County Hematology Oncology Specialists — Oxnard, California, United States
• James R. Berenson, MD Inc. — West Hollywood, California, United States
• PIH Health Hospital — Whittier, California, United States
• Rocky Mountain Cancer Centers — Denver, Colorado, United States
• University Cancer Institute (UCI) — Boynton Beach, Florida, United States
• Southeast Florida Hematology Oncology Group — Fort Lauderdale, Florida, United States
• Mayo Clinic in Florida — Jacksonville, Florida, United States
• Cancer Specialists of North Florida — Jacksonville, Florida, United States
• Watson Clinic Llp — Lakeland, Florida, United States
• Ocala Oncology Center — Ocala, Florida, United States
• Piedmont Cancer Institute — Atlanta, Georgia, United States
• Augusta University — Augusta, Georgia, United States
• Gwinnett Hospital System, Inc — Lawrenceville, Georgia, United States
• Nancy N. and J.C. Lewis Cancer & Research Pavillion -St. Josephs Candler Health System — Savannah, Georgia, United States
• Ingalls Memorial Hospital Cancer Research Center — Harvey, Illinois, United States
• Orchard Healthcare Research — Skokie, Illinois, United States
• Baptist Healthcare Systems, Inc. d/b/a Baptist Health Floyd — New Albany, Indiana, United States
• Physicians' Clinic of Iowa, P.C at PCI Main Building — Cedar Rapids, Iowa, United States
• Arizona Oncology Associates, PC - HAL — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.